TRODELVY DIN 02520788
Health Canada record
| Active ingredient(s) | SACITUZUMAB GOVITECAN 180 MG |
|---|---|
| Dosage form | Powder For Solution |
| Route | Intravenous |
| Schedule | SCHEDULE D; PRESCRIPTION |
| Class | Human |
| ATC | L01FX17 SACITUZUMAB GOVITECAN |
| Original market date | 22-Nov-2021 |
| Current status date | 22-Nov-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26736 | 2021-09-24 | New Drug Submission (NDS) |